This unique course provides a practical & in-depth understanding of HTA decision making across EU markets and will focus on the evidence generation underpinning a convincing value proposition to different HTAs. It will provide the tools to understand and critically appraise the evidence and studies required for HTA submissions, and to be able to put together an evidence plan including the underpinning data requirements and understanding the role of patients, cost-effectiveness models, access schemes and scientific advice.
The two-day training is structured in a way that participants can connect the strategic importance of process requirements to underlying of methods and optimal evidence. The training offers practical insights of former payer decision makers, method specialists and direct experience from HTA dossier submission and defense in different HTA driven markets. While HTA methods and processes are likely to change in the 2020’s significantly and rapidly, this course will allow understanding current practices, learning about future plans, and discussing potential changes in both process and requirements. During the course there will be opportunities to discuss indication -, market and molecule specifics, allowing for learning close to the participants challenges. The course will be interactive, participative and collaborative and build on the business aspirations of pharmaceutical and biotech companies and direct problem solving.
Join us & understand the strategies for patient access in an evolving value-based and patient-centric healthcare.
The role of patients in HTA decision-making
Optimizing the generation and the use of evidence in HTA
From Quality of Life to QALYs
Cost-effectiveness model & budget impact
HTA for cell & gene therapies
Access schemes & contracting
Shaping the EU HTA trend